Medicare AdvantageCoverageMedium impact
Barrett's Esophagus (CPB 0728, reviewed 2025-11-25)
Aetna·Gastroenterology, General Surgery, Cardiothoracic Surgery +2 more·Medical Policy
Effective date
Nov 25, 2025
We identified it
Aug 12, 2026
Summary
Aetna's Barrett's Esophagus policy (CPB 0728, effective 2025-11-25) establishes clear medical necessity criteria for covered treatments: radiofrequency ablation for low-grade dysplasia with specific biopsy requirements, and five approved interventions (endoscopic mucosal resection, esophagectomy, fundoplication, photodynamic therapy, radiofrequency ablation) for high-grade dysplasia. The policy designates numerous emerging tests and techniques as experimental/investigational, including AI detection tools, biomarker panels, cryotherapy, and laser therapies, which are not covered.
Action Required
By November 25, 2025: Billing team must update system edits and prior authorization protocols for Barrett's esophagus claims as follows: (1) CPT codes 43229 and 43270 (radiofrequency ablation) require documentation of histological low-grade dysplasia confirmed by 2+ endoscopies 3+ months apart before approval; (2) CPT codes 43211, 43254, 43100-43124, 43279-43280, 43286-43288, and 96570-96571 are covered only for high-grade dysplasia cases and require biopsy documentation; (3) CPT codes 43206, 43252, 0108U, 0114U, 0398U, 0506U and all experimental techniques (cryotherapy, argon plasma coagulation, laser therapy, etc.) must be denied as not medically necessary with explanation referencing experimental/investigational status; (4) Update encounter templates to require providers to document dysplasia grade and biopsy dates; (5) Notify providers of coverage criteria and experimental designations. Failure to implement will result in inappropriate approvals or denials.